HIGHLIGHTS
In aggregate, strategic brands grew 15% in 2021 reaching
EBIT grew 1% compared to 2020 and reached
Outlook 2022
- Revenue expected at
DKK 16.7 - 17.3 billion. -
Core EBIT expected at
DKK 3.6 - 4.0 billion. -
EBIT expected at
DKK 2.2 - 2.6 billion.
In connection with the quarterly corporate release, Lundbeck's President and CEO
"I am very pleased with the results in a challenging year. Our strategic and many of the mature brands continue to perform. The newest addition to our portfolio, Vyepti, continues to have good uptake where it has launched, and our plans to globalize this brand took a great step forward with EU approval last month. We have made great strides over the past year on our Expand and Invest to Grow strategy, and now have two very interesting phase II biotherapeutics projects. The proposed new capital structure with A and B-shares alsoannounced today is designed to expand our options for executing on our strategy over the long term. We have a strong future ahead of us."
Key figures:
DKK million | FY 2021 | FY 2020 | Growth |
Core Revenue* | 16,299 | 17,672 | (8%) |
Core EBIT* | 3,517 | 4,436 | (21%) |
Core EPS* (DKK) | 12.57 | 18.92 | (34%) |
Core EBIT margin* | 21.6% | 25.1% | |
Reported Revenue | 16,299 | 17,672 | (8%) |
Reported EBIT | 2,010 | 1,990 | 1% |
Reported EPS (DKK) | 6.63 | 7.96 | (17%) |
Reported EBIT margin | 12.3% | 11.3% |
*For definition of the measures "Core Revenue", "Core EBIT", "Core EBIT margin" and "Core EPS", see note 2 Core reporting
The newest product in the portfolio, Vyepti®, continues to grow strongly since its launch in
Core EBIT reached
Lundbeck has initiated a phase II PoC study for potential new treatment of migraine prevention with Lu AF09222, which represents a novel approach for potential treatment of migraine.
The Board of Directors proposes to pay a dividend of
Ottiliavej 9, 2500 Valby,
+45 3630 1311
info@lundbeck.com
https://news.cision.com/h--lundbeck-a-s/r/strong-operational-performance-with-continued-solid-growth-from-strategic-brands-in-q4-2021,c3501719
https://mb.cision.com/Main/18215/3501719/1532038.pdf
(c) 2022 Cision. All rights reserved., source